$MYOS Our product development is based on the understanding that myostatin antagonists and inhibitors are likely to enhance both muscle mass and bone strength. Myostatin is capable of inducing muscle atrophy via its inhibition of myoblast proliferation, increasing ubiquitin proteasomal activity and down-regulating activity of the IGF-Akt pathway.